Showing 2001-2010 of 2494 results for "".
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- Glauconix Biosciences Promotes Kimberly Southern to Chief Executive Officerhttps://modernod.com/news/glauconix-biosciences-promotes-kimberly-southern-to-chief-executive-officer/2477262/Glauconix Biosciences announced that its board of directors has appointed Kim Southern as Chief Executive Officer and a member of the Board of Directors effective immediately. Ms. Southern previously held the position of Chief Operating Officer. Since joining the company in May, Ms. Southe
- Report: Novartis Weighing Takeover Offer for The Medicines Companyhttps://modernod.com/news/report-novartis-weighing-takeover-offer-for-the-medicines-company/2477107/Novartis is considering making an offer to acquire The Medicines Company and is currently conducting due diligence on the drugmaker, Bloomberg reported Tuesday, citing people close to the matter. The sources suggested that The Medicines Company, which has a market value of about $4.7 bi
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Developmenthttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-corporate-development/2477091/EyePoint Pharmaceuticals announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lea
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- Regenxbio Announces License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314https://modernod.com/news/regenxbio-announces-exclusive-worldwide-license-agreement-with-clearside-biomedical-for-evaluation-of-in-office-delivery-platform-for-rgx-314/2476851/Regenxbio and Clearside Biomedical announced an option and license agreement for exclusive worldwide rights to Clearside’s proprietary, in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (AMD), diabetic
- Biophytis Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/biophytis-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2476604/Biophytis announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) in relation to a proposed initial public offering of American Depositary Shares representing ordinary shares of Biophytis. Biophytis has applied to list its shares